Results 31 to 40 of about 2,161,173 (316)

International Health

open access: yesInfectious Disease Clinics of North America, 1991
The Global Health Care Revolution of the Century, which began officially at Alma Ata in 1978, will help to achieve the Health for All goal by the year 2000. What will the next century usher in? Some of our achievements to date are highlighted, and lessons learned and yet to be learned are emphasized.
openaire   +4 more sources

The anabolic steroid stanozolol is a potent inhibitor of human MutT homolog 1

open access: yesFEBS Letters, EarlyView.
MutT homolog 1 (MTH1) is a member of the NUDIX superfamily of enzymes and is an anticancer drug target. We show that stanozolol (Stz), an anabolic steroid, is an unexpected nanomolar inhibitor of MTH1. The X‐ray crystal structure of the human MTH1–Stz complex reveals a unique binding scaffold that could be utilized for future inhibitor development ...
Emma Scaletti Hutchinson   +7 more
wiley   +1 more source

International Health Regulations (2005) [PDF]

open access: yesThe Lancet, 2005
link_to_subscribed_fulltext
Merianos, A, Peiris, M
openaire   +5 more sources

ACSS2 involved in acetyl‐CoA synthesis regulates skeletal muscle function

open access: yesFEBS Letters, EarlyView.
The enzyme acyl‐coenzyme A synthetase short‐chain family member‐2 (ACSS2) catalyzes the conversion of acetate to acetyl‐CoA, but its function in skeletal muscle is unclear. We studied ACSS2 deficiency in mouse and fly models. Skeletal muscle from the mouse model showed atrophic fibers, excess lipid, and depleted NADH.
Mekala Gunasekaran   +6 more
wiley   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

open access: yesMolecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia   +17 more
wiley   +1 more source

Historical Evolution and the Future of Global Health Security

open access: yesJournal of Nature and Science of Medicine, 2022
Health security has become an integral part of global health after many epidemics, the latest of which was the COVID-19 pandemic, from which the world is still suffering. The term “health security” was first used in the mid-twentieth century.
Anas A Khan   +5 more
doaj   +1 more source

Global health security and the International Health Regulations [PDF]

open access: yesBMC Public Health, 2010
Global nuclear proliferation, bioterrorism, and emerging infections have challenged national capacities to achieve and maintain global security. Over the last century, emerging infectious disease threats resulted in the development of the preliminary versions of the International Health Regulations (IHR) of the World Health Organization (WHO).
Jon Kim Andrus   +3 more
openaire   +4 more sources

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

open access: yesMolecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani   +14 more
wiley   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

open access: yesMolecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu   +12 more
wiley   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

open access: yesMolecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy